
Opinion|Videos|June 27, 2024
Overview of Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Author(s)Guillermo Garcia-Manero, MD
Guillermo Garcia-Manero, MD, provides a brief overview of lower-risk myelodysplastic syndromes (LR-MDS).
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following questions:
- Provide a brief overview of lower-risk myelodysplastic syndromes (LR-MDS)?
- What are the clinical hallmarks of LR-MDS?
- As anemia is present in >90% of cases, what are available therapies to alleviate anemia?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















